Anastasopoulou, S., Harila‐Saari, A., Als‐Nielsen, B., Eriksson, M. A., Heyman, M., Johannsdottir, I. M., Marquart, H. V., Niinimäki, R., Pronk, C. J., Schmiegelow, K., Vaitkeviciene, G., Thastrup, M., & Ranta, S. (2022). Does minimal central nervous system involvement in childhood acute lymphoblastic leukemia increase the risk for central nervous system toxicity? Pediatric Blood & Cancer, 69(7). https://doi.org/10.1002/pbc.29745
Does minimal central nervous system involvement in childhood acute lymphoblastic leukemia increase the risk for central nervous system toxicity?
|Author:||Anastasopoulou, Stavroula1,2; Harila-Saari, Arja3; Als-Nielsen, Bodil4;|
1Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
2Department of Women's and Children's Health, Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden
3Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
4Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark
5Department of Women's and Children's Health, Neuropediatric Unit, Karolinska Institutet, Stockholm, Sweden
6Department of Pediatric Hematology/Oncology, Oslo University Hospital, Oslo, Norway
7Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
8Department of Children and Adolescents, Oulu University Hospital and University of Oulu, PEDEGO Research Unit, Oulu, Finland
9Childhood Cancer Centre, Skåne University Hospital, Lund, Sweden
10Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark
11Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania
|Online Access:||PDF Full Text (PDF, 0.2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022123074131
John Wiley & Sons,
|Publish Date:|| 2022-12-30
Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) implicates enhanced intrathecal chemotherapy, which is related to CNS toxicity. Whether CNS involvement alone contributes to CNS toxicity remains unclear. We studied the occurrence of all CNS toxicities, seizures, and posterior reversible encephalopathy syndrome (PRES) in children with ALL without enhanced intrathecal chemotherapy with CNS involvement (n = 64) or without CNS involvement (n = 256) by flow cytometry. CNS involvement increased the risk for all CNS toxicities, seizures, and PRES in univariate analysis and, after adjusting for induction therapy, for seizures (hazard ratio [HR] = 3.33; 95% confidence interval [CI]: 1.26–8.82; p = 0.016) and PRES (HR = 4.85; 95% CI: 1.71–13.75; p = 0.003).
Pediatric blood & cancer
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3123 Gynaecology and paediatrics
This study was supported by grants provided by the Swedish Childhood Cancer Fund, Sweden.
© 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.